Multiple Myeloma Research Consortium Names LabVantage as Preferred Biobanking Partner
News Apr 07, 2006
The Multiple Myeloma Research Consortium (MMRC) has selected LabVantage Solutions, Inc., a provider of biospecimen management solutions, to serve as its preferred biobanking partner.
Under this partnership, LabVantage has implemented its Sapphire BioBanking Solution to support the collection, banking, and tracking of biospecimens through the MMRC Tissue Bank and to support related data generated by MMRC research and discovery efforts.
Tailored by LabVantage for the MMRC, this biobanking solution will streamline and optimize the MMRC's collaborative research efforts by providing intricate chain of custody for biospecimen transfers, detailed location and shipment management of biospecimens, aliquot, derivative, and pooled sample tracking, and electronic signature capture upon transfer and disposition of biospecimens.
These functions will ensure that the MMRC Tissue Bank remains in compliance with government regulated Good Laboratory Practices (GLP) and will guarantee that biospecimens used in MMRC research and discovery efforts are of the very highest quality.
"Accurate, quality-focused, and efficient management of biospecimens and related clinical and experimental data by this solution will play an invaluable role in the MMRC's ability to rapidly advance pre-clinical projects, clinical trials, and correlative studies," said Steven Young, Executive Director, MMRC.
LabVantage's Sapphire BioBanking Solution also enables the MMRC to manage comprehensive clinical data, medical histories, and critical genomic and phenotypic data associated with biospecimens under compliance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA), other regulatory requirements, and Good Clinical Practices (GCP).
"The Sapphire BioBanking Solution will enhance the MMRC's ability to manage the increasing number of biospecimens accrued into the MMRC Tissue Bank and used across MMRC laboratories-functions that are essential in advancing the MMRC's research and drug development efforts," said Jim Aurelio, President & CEO, LabVantage.
"We are pleased that MMRC was able to implement Sapphire in less than two months, enabling the benefits of the solution to be realized by MMRC and, ultimately multiple myeloma patients, that much sooner," he added.